. Author manuscript; available in PMC: 2017 Nov 30.

Published in final edited form as: Pharmacogenomics J. 2016 Aug 23;17(6):521–527. doi: 10.1038/tpj.2016.60

Table 1.

Demographic data for all patients included in the analysis.

Characteristic		n=246
Self-Reported Race	White	220 (89.4%)
	Black	20 (8.1%)
	Other/Unknown	6 (2.4%)
Age	At enrollment	59 (35–83)
Size	Body Mass Index (kg/m²)	29.3 (20.3–53.4)
Renal Function	1^st Tertile (CrCl > 108.5 mL/min)	47 (19.1%)
	2^nd Tertile (83.0 < CrCl ≤ 108.5)	47 (19.1%)
	3^rd Tertile (CrCl ≤ 83.0 mL/min)	47 (19.1%)
	Unknown	105 (42.7%)
Hepatic Function	Impaired (AST or ALT > 40)	19 (7.7%)
	Normal (AST and ALT ≤ 40)	225 (91.5%)
	Unknown	2 (0.1%)
Prior Chemotherapy Treatment	Yes	109 (44.3%)
Prior Chemotherapy Treatment	No	137 (55.7%)
Sample collection time (months on exemestane)	1	41 (16.7%)
Sample collection time (months on exemestane)	3	205 (83.3%)

Data reported as count (percentage) or median (range)